ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Search through all presentations

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...4/The-best-approach-to-oligometastatic-NSCLC

Date: 27 Sep 2014
Presenter: Jaroslaw Kuzdzal
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ge-non-small-cell-lung-cancer-NSCLC-patients

AimPreviously, we reported on early weight loss (WL) and muscle weakness during CCRT that could not be attributed to acute radiation esophagitis (ARIE). Thus, we here hypothesized that early WL reflects...

Date: 27 Sep 2014
Presenter: Lizza Hendriks
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-met-negative-expression-ML28941-C-TONG-1306

BackgroundNon-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations show excellent clinical benefit to Erlotinib. Since EGFR wild type constitutes approximately...

Date: 27 Sep 2014
Presenter: Zhang Li
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Non-Small-Cell Lung Cancer, Metastatic, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...d-MPM-with-deregulated-FGF-pathway-signaling

BackgroundFP1039/GSK3052230 (GSK230) is a soluble fusion protein that acts as a ligand trap by sequestering fibroblast growth factors (FGFs) involved in tumor growth.

Date: 27 Sep 2014
Presenter: Pilar Garrido
Resources: Abstract
Topics: Drug Development, Non-Small-Cell Lung Cancer, Locally Advanced, Mesothelioma, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...us-cell-SCC-non-small-cell-lung-cancer-NSCLC

BackgroundIn a phase 3 trial, nab-P/C vs solvent-based paclitaxel + C demonstrated a 68% improvement in ORR (41% vs 24%; P < 0.001) and a trend toward improved overall survival (OS; median 10.7 vs 9.

Date: 27 Sep 2014
Presenter: David Spigel
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced

http://oncologypro.esmo.org/Meeting-Resourc...-locally-advanced-non-small-cell-lung-cancer

AimComputed tomography (CT) scan, despite its limitation of imaging sequence, is the standard tool for response assessment following chemo-radiation in locally advanced non-small cell lung cancer (LA-NSCLC).

Date: 27 Sep 2014
Presenter: Soumyajit Roy
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Locally Advanced, Imaging, Diagnosis and Staging

http://oncologypro.esmo.org/Meeting-Resourc...s-using-data-from-randomized-clinical-trials

AimResults from randomized clinical trials (RCTs) evaluating the efficacy of chemotherapy are typically reported as relative risk or difference in median survival on a group level.

Date: 27 Sep 2014
Presenter: Rob van Kruijsdijk
Resources: Abstract
Topic: Non-Small-Cell Lung Cancer, Locally Advanced

http://oncologypro.esmo.org/Meeting-Resourc...nced-lung-cancer-by-emphysema-quantification

AimRadiation pneumonitis (RP) is one of the most crucial adverse events of definitive chemoradiotherapy for the treatment of locally advanced lung cancer. Although chronic obstructive pulmonary disease ...

Date: 27 Sep 2014
Presenter: Shuntaro Tokunaga
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Complications of Treatment, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...bjects-with-non-small-cell-lung-cancer-NSCLC

AimVeliparib (V; ABT-888) is a potent, orally bio-available PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutic agents, triggering cell death and enhancing efficacy.

Date: 27 Sep 2014
Presenter: Hidenori Mizugaki
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Non-Small-Cell Lung Cancer, Metastatic

http://oncologypro.esmo.org/Meeting-Resourc...resected-non-small-cell-lung-cancer-patients

AimWe tested the hypothesis that the circulating tumor cells (CTCs) in preoperative peripheral blood (PPB) and intraoperative pulmonary venous blood (IPVB) could predict poor long-term survival in surgically resected NSCLC patients.

Date: 27 Sep 2014
Presenter: ZhiDong Liu
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Locally Advanced, Translational Research